Magnetic Ventures

Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhance the expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines.

Weave is a biomedicine-focused company based in the United States that offers an artificial intelligence collaboration platform. This platform specializes in generating regulatory submissions, including Investigational New Drug applications. By automating clinical note abstraction pipelines and linking multimodal datasets, Weave enhances the efficiency of research and development processes. The platform facilitates collaboration among regulatory, research, and clinical teams, allowing them to organize, edit, and summarize source materials into submission-ready documents within a day. This capability accelerates the discovery of various data modalities, empowering researchers to make faster and more informed decisions in drug development.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Project Eaden is a company focused on the development and licensing of innovative technologies aimed at producing sustainable food and meat alternatives. By integrating advanced technology with food production, Project Eaden creates sustainable food products designed to meet consumer cravings for meat. The company's platform offers alternatives that provide a more environmentally friendly substitute for traditional beef and beef products, promoting sustainability in the food industry.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Spotlight Therapeutics is a biotechnology company based in Hayward, California, founded in 2017. It specializes in developing gene editing therapeutics that target specific cell populations directly within the body. The company's platform utilizes CRISPR technology to deliver programmable nucleases to selected cell types in vivo, enabling precise and selective gene editing. Spotlight Therapeutics focuses on creating next-generation treatments for various diseases, with initial programs in immuno-oncology, ophthalmology, and hematology.

Resilience, established in 2020 and headquartered in La Jolla, California, is a biopharmaceutical manufacturing and technology company. It specializes in providing end-to-end manufacturing and development solutions for complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Resilience invests in developing new manufacturing technologies to ensure rapid, safe, and scalable production, thereby enhancing patient access to these treatments. The company partners with biopharmaceutical companies to focus on breakthrough discoveries while Resilience manages the manufacturing process, safeguarding supply chains against future disruptions.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.

AppliedVR, Inc. is a Los Angeles-based company that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management in settings such as hospitals and surgery centers. Founded in 2013, AppliedVR has established strategic partnerships with institutions like Cedars-Sinai and Children's Hospital Los Angeles. The company's flagship product, EaseVRx, is a pioneering VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. This innovative treatment leverages principles of cognitive behavioral therapy and mindfulness to help patients manage chronic pain by changing their pain perception and fostering new coping skills. EaseVRx allows patients to self-administer therapy at home, facilitating remote care and improving access to effective pain management solutions. Through its clinically validated and comprehensive approach, AppliedVR seeks to address the complexities of chronic pain and enhance overall quality of life for patients.

SameSky Health is a developer of a patient engagement platform designed to connect payers, providers, and health systems with multicultural Medicare patient populations. The company offers integrated services through a web and application-based platform that includes multi-channel messaging, care navigation, and data insights. By addressing the specific needs of culturally diverse populations, SameSky Health aims to guide these individuals through the complexities of the healthcare system. The platform enhances client engagement, reduces unnecessary emergency room visits, and improves overall health outcomes and quality of care.

Resilience, established in 2020 and headquartered in La Jolla, California, is a biopharmaceutical manufacturing and technology company. It specializes in providing end-to-end manufacturing and development solutions for complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Resilience invests in developing new manufacturing technologies to ensure rapid, safe, and scalable production, thereby enhancing patient access to these treatments. The company partners with biopharmaceutical companies to focus on breakthrough discoveries while Resilience manages the manufacturing process, safeguarding supply chains against future disruptions.

Resilience, established in 2020 and headquartered in La Jolla, California, is a biopharmaceutical manufacturing and technology company. It specializes in providing end-to-end manufacturing and development solutions for complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Resilience invests in developing new manufacturing technologies to ensure rapid, safe, and scalable production, thereby enhancing patient access to these treatments. The company partners with biopharmaceutical companies to focus on breakthrough discoveries while Resilience manages the manufacturing process, safeguarding supply chains against future disruptions.

Emme, Inc. is a healthcare technology company based in San Francisco, California, focused on improving women's health, particularly in the area of birth control. The company has developed an integrated smart case device and mobile application designed to help women take their birth control pills consistently. This multi-sensor technology tracks pill consumption, alleviates the need for users to remember to take their medication, and alerts those at risk of unintended pregnancy when back-up contraception is necessary. Additionally, the accompanying app provides users with a comprehensive overview of their health by enabling tracking of menstrual cycles, moods, and side effects. Emme aims to modernize the birth control experience, making it more user-friendly and aligned with the demands of contemporary life.

Amagma Therapeutics is a biotechnology company founded in 2019 and based in Waltham, Massachusetts. The company focuses on the discovery and development of antibody therapeutics aimed at addressing inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma's therapies target overactive extracellular proteases, which lead to tissue damage and contribute to widespread inflammatory responses. By developing these innovative treatments, Amagma aims to enhance therapeutic efficacy while ensuring patient safety in the management of human diseases linked to enzyme dysfunction.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York. It focuses on developing innovative therapeutics aimed at preventing cancer relapse and metastasis, which are significant contributors to cancer-related mortality. The company’s therapeutic pipeline addresses mechanisms of treatment resistance and utilizes advanced technologies, including artificial intelligence and machine learning, to analyze multi-omic and phenotypic profiles of tumors. This approach aims to generate insights that link tumor characteristics to clinical outcomes, ultimately striving to improve patient survival and quality of life by enabling longer, cancer-free lives.